Details for New Drug Application (NDA): 210737
NDA 210737 describes REDITREX, which is a drug marketed by Nordic Grp and is included in one NDA. Additional details are available on the REDITREX profile page.
The generic ingredient in REDITREX is methotrexate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the methotrexate profile page.
The generic ingredient in REDITREX is methotrexate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the methotrexate profile page.
Summary for 210737
| Tradename: | REDITREX |
| Applicant: | Nordic Grp |
| Ingredient: | methotrexate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 210737
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 7.5MG/0.3ML (7.5MG/0.3ML) | ||||
| Approval Date: | Nov 27, 2019 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 10MG/0.4ML (10MG/0.4ML) | ||||
| Approval Date: | Nov 27, 2019 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 12.5MG/0.5ML (12.5MG/0.5ML) | ||||
| Approval Date: | Nov 27, 2019 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
